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Introduction
Continuous positive airway pressure (CPAP) is the gold 
standard treatment for obstructive sleep apnoea (OSA) (1-4). 
CPAP is very effective in abolishing apnoea and hypopnoea, 
and reverses the pathophysiologic consequences of OSA. Its 
effectiveness depends on sufficient and regular usage. 
Randomised controlled trials (RCTs) in patients with 
moderate-to-severe OSA have shown that treatment 
with CPAP reduces excessive daytime sleepiness (1) and 
improves driving performance (5) and health related-
quality of life (1). However, many conclusions as to the 
effects of CPAP treatment in OSA come from population-
based epidemiological studies, and robust evidence from 
randomised controlled interventional trials is often 
missing. There is still a need for well-designed RCTs to 
study the effects of CPAP therapy on diverse physiological 
and clinically relevant outcomes, e.g., cardio- and 
cerebrovascular events. Conventional CPAP trials are 
typically limited by the unpredictable and often suboptimal 
CPAP adherence in treatment-naïve patients, which lead to 
underestimation of treatment effects. Subjects who do not 
tolerate CPAP well, and use it only intermittently during 
the night, might even have negative effects such as disturbed 
sleep architecture and elevated blood pressure (6). This 
suboptimal CPAP adherence hampers the interpretation of 
the often cumbersome and expensive conventional CPAP 
RCTs. Furthermore, there is interest in novel treatment 
modalities as alternatives to CPAP, since the latter is not 
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tolerated by all patients, and compliance with this treatment 
is often suboptimal. Thus, a rapid assessment tool for these 
new treatments would be helpful. We therefore suggest a 
short-term CPAP withdrawal as an effective study model to 
investigate both the consequences of untreated OSA, and 
potential treatment alternatives to CPAP. What evidence 
exists to justify this approach?
The CPAP withdrawal model
In the CPAP withdrawal model, patients previously 
diagnosed with OSA, and effectively treated and compliant 
with CPAP, are randomised to either continue therapeutic 
CPAP or to withdraw it by using a subtherapeutic sham-
CPAP device, for a short period (e.g., 2 weeks). This 
controlled model can be conducted with double-blind 
randomisation. Measurements are performed at baseline on 
CPAP, and at follow-up on either CPAP (control group) or 
sham-CPAP (intervention group) (see Figure 1). Additional 
repeated measurements after randomisation over the 
experimental period can be inserted to assess the gradual 
changes in the outcomes. Furthermore, the traditional 
two-arm CPAP withdrawal model can be extended to a 
several-arm RCT to study therapy alternatives by adding 
one or more extra CPAP-withdrawal arms using the novel 
treatment(s). Therefore, the novel treatments can be 
compared to both the continuing on CPAP, and/or to the 
withdrawal group serving as an untreated control group 
with full return of OSA.
This model can study medically well-characterised and 
carefully selected patients with OSA from large cohorts who 
are already being treated with CPAP. Sleep centres or CPAP 
providers usually have databases of treated OSA patients, 
including information on their therapy compliance, thus 
allowing fast recruitment. Carefully selected eligibility 
criteria (e.g., inclusion of patients with high long-term 
CPAP adherence and exclusion of professional drivers) can 
be utilised to make the design effective and safe. 
In general, persistence of OSA is first confirmed before 
study inclusion by home overnight pulse-oximetry at the 
end of a four-night period off CPAP. This is important since 
the time of diagnosis of OSA and CPAP initiation might 
have been some years ago, and potential causal factors, such 
as obesity, might have changed.
Discussion
Physiological effects of CPAP withdrawal
We have shown that a short-term CPAP withdrawal results 
in recurrence of OSA as indicated by changes in sleep 
study parameters. This recurrence of OSA in response to 
Figure 1 The traditional CPAP withdrawal model. Patients previously diagnosed with OSA compliant with CPAP for more than 1 year and 
with conferment persistence of OSA during a four-day period off CPAP during a pre-trial screening are included. After a baseline sleep study 
on CPAP and baseline assessments, patients are randomised to either continue therapeutic CPAP or to withdraw it by the use of a sham-
device before returning for a follow-up sleep study and follow-up assessments after 2 weeks on the respective treatment. CPAP, continuous 
positive airway pressure; OSA, obstructive sleep apnoea.
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CPAP therapy withdrawal was associated with a number 
of consequences: a deterioration of daytime symptoms and 
psychomotor performance; increases in blood pressure, heart 
rate, and urinary catecholamines; peripheral endothelial 
dysfunction; disturbances of cardiac repolarisation; and 
changes in the metabolic breath profile (7-10). However, we 
have also demonstrated that short-term CPAP withdrawal 
does not result in impaired myocardial perfusion, despite 
the increase in blood pressure and other adverse effects of 
OSA (11). This was an important message for patients with 
OSA, and for physicians treating such patients, since taking 
a CPAP holiday, for several days or more, is common even 
in compliant patients. Contrary to our prior hypothesis, 
we found that the return of intermittent hypoxia did 
not increase oxidative stress, but may have decreased it, 
potentially explained by hypoxic preconditioning (12). 
The most important findings of the trials using the 
CPAP withdrawal protocol are described below (also see 
Figures 2,3).
The first proof of concept study defined the physiological 
effects of CPAP withdrawal on OSA recurrence, daytime 
symptoms, blood pressure, endothelial function, and 
systemic inflammation at 1 and 2 weeks after CPAP 
withdrawal (7). Withdrawal of CPAP resulted in an 
increased apnoea-hypopnoea-index (AHI) at 1 and 2 weeks 
to a comparable degree (mean increase in AHI +31.9 (95% 
CI: +20.1 to +43.7) and +33.5 (95% CI: +22.4 to +44.6), 
respectively; P<0.001 for both comparisons) compared to 
continuation of CPAP (7). However, subjective sleepiness, as 
assessed by the Epworth Sleepiness Scale (ESS), increased 
gradually at 1 and 2 weeks in the CPAP withdrawal group, 
compared to the control group (mean rise in ESS +1.9 (95% 
CI: +0.4 to +3.3) and +2.7 (95% CI: +1.2 to +4.3); P=0.015 
and P<0.001, respectively) (7). Despite increased daytime 
sleepiness, short-term CPAP withdrawal was not associated 
with deterioration in psychomotor performance (divided 
attention driving simulator and psychomotor vigilance 
task) (7). This study established the CPAP withdrawal 
model and has shown that CPAP therapy withdrawal 
usually leads to a rapid recurrence of OSA, accompanied 
by a gradual return of subjective daytime sleepiness. 
Additionally, this RCT showed that therapy withdrawal in 
OSA leads to increases in markers of sympathetic activity 
(but not systemic inflammation) and endothelial dysfunction 
as assessed by flow-mediated dilatation of the brachial artery 
—a well validated method to assess endothelial function (7).
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Figure 2 Physiological effects of 14 days of CPAP withdrawal 
on cardiovascular outcomes in obstructive sleep apnoea. CPAP, 
continuous positive airway pressure; FMD, flow-mediated 
dilatation of the brachial artery (endothelial function); MBF, 
hyperaemic myocardial blood flow (myocardial perfusion in 
ammonia-positron emission tomography); SBP, systolic blood 
pressure; DBP, diastolic blood pressure; HR, heart rate; BPV, blood 
pressure variability; HRV, heart rate variability; QTc, corrected 
QT interval. Statistically significant treatment effects (P<0.05) are 
highlighted (*). 
Figure 3 Effects of 14 days of CPAP withdrawal on blood and 
urinary markers in obstructive sleep apnoea. Statistically significant 
treatment effects (P<0.05) are highlighted (*). CPAP, continuous 
positive airway pressure.
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Based on these findings, the hypothesis was postulated 
that CPAP withdrawal also results in dysfunction of 
the microvasculature, and therefore in impairment 
of myocardial perfusion. To answer this question, a 
randomised controlled CPAP withdrawal trial assessing 
the change in myocardial blood flow during adenosine-
induced vasomotor stress assessed by 13N-ammonia positron 
emission tomography was conducted (11). This is the 
current gold standard for the quantification of myocardial 
blood flow (13). We found that myocardial blood flow does 
not change in response to recurrence of moderate to severe 
OSA after 2 weeks of CPAP withdrawal when compared 
to continuing CPAP therapy (11). CPAP withdrawal 
also had no effect on other microvascular beds, e.g., the 
dermal microcirculation (11). The confidence intervals 
of the treatment effect clearly demonstrated that any 
relevant effect on myocardial perfusion can be excluded 
(treatment effect on hyperaemic myocardial blood flow: 
−0.01 mL/min/g, 95% CI: −0.33 to +0.24 mL/min/g, 
P=0.91; minimally clinically important difference 
0.75 mL/min/g) (11). This finding was unexpected 
because, in theory, recurrence of OSA may impair 
myocardial perfusion by several possible mechanisms, 
including endothelial dysfunction that could result from 
augmented sympathetic activity, increased oxidative 
stress due to intermittent hypoxia, as well as increased 
oxygen demand from the increased cardiac work load 
due to accelerated heart rate and elevated blood pressure. 
However, this study clearly showed that there is no 
immediate adverse effect of CPAP therapy withdrawal 
on myocardial perfusion in patients with moderate to 
severe OSA, despite the recurrence of OSA and relevant 
increases in blood pressure. We concluded that OSA 
patients are unlikely to be at risk for acute myocardial 
ischemia during short periods of treatment interruption 
such as on vacation. This finding was an important 
message for both clinicians and patients with OSA, since 
“CPAP holidays” are common.
Whereas there is robust evidence for increased 
sympathetic activity as the most relevant contributing factor 
for the systemic consequences of OSA, there is inconsistent 
data on the role of intermittent hypoxia, oxidative stress and 
systemic inflammation as potential cause of cardiovascular 
consequences. In order to examine whether withdrawal of 
CPAP and thus reactivation of intermittent hypoxia would 
result in a rise of markers of oxidative stress, 59 patients 
with moderate to severe OSA were randomised to either 
continue therapeutic CPAP or to subtherapeutic CPAP 
(sham) (12). However, despite re-occurrence of intermittent 
hypoxia, there was no evidence of an increase in markers 
of oxidative stress in response to recurrence of OSA, 
e.g., early morning blood malondialdehyde—a sensitive 
marker of oxidative stress. Unexpectedly, OSA reactivation 
was associated with a significant reduction in urinary 
F2-isoprostane (P=0.002 compared to the control group) 
that showed a correlation with the oxygen desaturation 
index (ODI) (r=−0.41, P=0.001) (12). However, this finding 
was confounded by a rise in overnight urinary volume in 
those with returning OSA (14). This finding implied a 
reduction in oxidative stress and possible explanation was a 
significant increase in superoxide dismutase—a marker of 
hypoxic pre-conditioning—found in patients with returning 
OSA compared to those remaining on CPAP (12).
Exhaled breath contains metabolic information on the 
pathophysiological state. We used the CPAP withdrawal 
protocol to test whether a disease specific profile of exhaled 
breath in patients with OSA can be detected by real-time 
exhaled breath analysis by mass spectrometry. Untargeted 
exhaled breath analysis was used to define the effect of 
metabolic changes on the breath profile (10). 
Indeed, recurrence of OSA was accompanied by a 
specific change in exhaled breath pattern. The panel of 
discriminating mass-spectral features allowed separation 
between treated and untreated OSA with a sensitivity of 
92.9% and a specificity of 84.6% (10). There was also a 
good correlation between changes in the breath signal 
intensity of these features, and the change in ODI as a 
measure of OSA severity (10). These data on OSA-specific 
compounds in exhaled breath supported the association 
of OSA with increased sympathetic activity and lipid 
peroxidation, as well as evidence of a change in gut flora. 
This withdrawal study has shown that exhaled breath 
analysis by real-time untargeted mass spectrometry allows 
rapid and non-invasive recognition of returning OSA with 
good sensitivity and specificity, as well as the identification 
of new biomarkers. This approach of breath profiling in 
OSA might be useful in both screening for OSA as well as 
monitoring treatment adherence.
Using data from this experimental protocol, we 
have tested additional hypotheses based on preliminary 
evidence from other experimental studies, with a focus on 
mechanisms explaining the observed increased incidence 
of cardiovascular disease in OSA. The blood pressure 
lowering effect of CPAP therapy, in meta-analyses based 
on RCTs in previously untreated patients, is probably 
underestimated due to suboptimal CPAP usage (15). To 
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measure the withdrawal effect on blood pressure and 
to find potential clinical predictors of blood pressure 
response to OSA treatment, data from 149 optimally 
CPAP compliant patients, included in randomised-
controlled CPAP withdrawal trials, were analysed (8). 
Consistent with the previous smaller withdrawal studies, 
there was a significant increase in morning blood pressure 
and heart rate in the withdrawal group compared to the 
continuing therapeutic CPAP group. OSA recurrence 
was associated with a clinically relevant increase in home 
systolic and diastolic blood pressure of approximately 
9 and 8 mmHg, respectively (8). This effect on blood 
pressure is considerably higher than in conventional CPAP 
trials. This might be explained by a maximal treatment or 
withdrawal effect due to the high prior CPAP adherence 
in the study population. The effect on blood pressure was 
underestimated when office values, instead of home values, 
were used. With this in mind, home blood pressure, instead 
of office blood pressure measurements, should probably 
be used as the most sensitive blood pressure outcome in 
clinical trials.
This analysis has established that the blood pressure 
lowering effects of CPAP are highest in those with the most 
severe OSA, and in those on several antihypertensive drugs (8).
In addition to systemic hypertension, blood pressure 
variabil i ty has been suggested as an independent 
cardiovascular risk factor (16). However, within the CPAP 
withdrawal trials, randomising 183 patients to either 
continue therapeutic CPAP or to withdraw it, there was 
only a negligible increase in within-visit variability in 
systolic office blood pressure, whereas there was no effect 
of withdrawing CPAP on other short-term blood pressure 
variability indices (within-visit), or on intermediate-
term blood pressure variability indices (visit-to-visit, 
day-to-day) (17). The hypothesis that OSA contributes 
to vascular damage via elevated daytime blood pressure 
variability could not be supported.
Untreated OSA has been associated with cardiac 
arrhythmias and increased incidence of sudden cardiac 
death (18,19). Disturbed cardiac repolarisation, induced by 
autonomic dysfunction, has been suggested as a potential 
underlying mechanism of arrhythmogenesis. Analysing 
electrocardiographic data from a CPAP withdrawal study, 
we found that CPAP withdrawal led to a statistically 
significant prolongation of repolarisation and an increase in 
the dispersion of transmural cardiac repolarisation compared 
to continuing therapeutic CPAP (9). These changes 
showed a good correlation with the change in AHI (9). 
These findings provided a potential mechanistic link 
between OSA and cardiac arrhythmias.
Patients with OSA suffer from cognitive impairment 
and have an increased risk of stroke in observational 
studies (20). Using the randomised controlled CPAP 
withdrawal protocol, it was demonstrated that OSA is 
associated with intermittent and sustained nocturnal 
cerebral tissue hypoxia, to a clinically relevant degree 
reported to cause functional impairment (21,22). This 
study suggested that CPAP may prevent the risk of 
nocturnal ischaemic cerebral damage.
Most data on the association between OSA and possible 
activation of (hypoxia-induced) inflammatory pathways, 
potentially promoting the observed adverse cardiovascular 
risk, comes mainly from cell culture, animal or case 
control studies. RCTs on the effect of CPAP therapy on 
markers of systemic inflammation are inconclusive (23,24). 
Interpretation is additionally complicated due to the 
common co-existence of OSA and obesity (potential 
adipose tissue-mediated inflammation). In 109 patients 
with OSA included in CPAP withdrawal trials (a real 
life model of intermittent hypoxia) levels of selected 
vascular inflammatory markers linked to hypoxia and 
previously reported to be altered in OSA were analysed; 
the endothelium-derived protein endocan, the endothelial-
derived vasodilator adrenomedullin, and the vasoconstrictor 
endothelin-1 (25). Of interest, CPAP withdrawal led 
to a small but significant decrease in adrenomedullin 
compared to continuation of therapeutic CPAP. However 
levels of hypoxia-induced and other endothelial-derived 
inflammatory markers and vasoconstrictive substances 
were unchanged (25). This is not in line with observational 
studies in OSA and non-human models of intermittent 
or sustained hypoxia. The return of OSA upon CPAP 
withdrawal was associated with a significant increase in 
endothelial cell-derived microvesicles (26). Of interest, a 
more specific exploratory analysis revealed a significant 
increase in platelet-derived and procoagulant microvesicles 
in response to CPAP withdrawal (27). However, the 
hypothesis of potential effects of OSA on the coagulation 
system has to be further tested. 
Currently, there are ongoing randomised controlled 
CPAP withdrawal trials to establish the effects of OSA on 
retinal vascular reactivity (ISRCTN78082983), and on 
cerebrovascular reactivity (NCT02493673). Additionally, 
there is an ongoing CPAP withdrawal trial to evaluate 
whether patients with suboptimal CPAP usage still benefit 
from treatment or not (NCT02781740).
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The withdrawal model for assessment of treatment 
alternatives
The CPAP withdrawal model can not only be applied to 
evaluate the pathophysiological consequences of OSA, 
but also to rapidly study the response to novel treatment 
approaches. The Provent® trial was a three-arm RCT 
studying the efficacy of a nasal expiratory positive airway 
pressure device to prevent the recurrence of OSA following 
the CPAP withdrawal. Sixty-seven patients with OSA, 
previously on CPAP, were randomised to either continue 
CPAP or to use the nasal EPAP-device or a sham-nasal 
EPAP-device (28). The trial found no therapeutic effect 
of Provent® on OSA compared to sham-Provent, and 
thus concluded that the nasal EPAP device is ineffective 
and cannot be recommended as an alternative treatment 
for OSA. Recently, a CPAP withdrawal RCT on the 
effects of supplemental oxygen versus sham oxygen on 
the blood pressure rise seen following the return of OSA 
(ISRCTN17987510) was completed. This trial hopes to 
answer the question whether intermittent hypoxia is, or is 
not, the major cause of the rise in diurnal blood pressure 
in OSA (29), as supplemental oxygen greatly attenuates 
the hypoxic dips without significantly affecting the AHI 
or arousals (30). Preliminary results suggest that the blood 
pressure rise following CPAP withdrawal is significantly 
attenuated by the supplemental oxygen (30).
Other studies using therapy withdrawal in OSA
The concept  of  s tudying the pathophysiologica l 
consequences of OSA by a CPAP therapy withdrawal has 
been also been applied by other groups (31). However, 
a short-term withdrawal (often just for one night) has 
mainly been used to study OSA in uncontrolled and non-
randomised studies (31-43). A return of OSA, however to 
a lesser extent, was described even after one night of CPAP 
withdrawal associated with somnolence, decreased alertness 
and impaired vigilance (31-43). One crossover RCT used 
CPAP withdrawal to study the effects of OSA on metabolic 
markers (44). Another RCT found an improvement in 
olfactory function on CPAP which was reversed upon 
CPAP withdrawal (45). Additionally, one group also used 
CPAP therapy withdrawal to study modafinil as a treatment 
alternative (46-48). They finally concluded that modafinil is 
a potential short-term treatment option during acute CPAP 
withdrawal since it improved performance. Withdrawal of 
treatment effects have not only been studied using CPAP, 
but also in electrical stimulation as a treatment of OSA (49).
Summary of the findings from the CPAP withdrawal 
model
In conclusion, the findings from the CPAP withdrawal 
RCTs have provided robust evidence for increased 
sympathetic activity in OSA associated with a considerable 
blood pressure increase, relevant cerebral hypoxia, and 
disturbed cardiac repolarisation. Furthermore, the blood 
pressure lowering effect of CPAP was further proven. 
Additionally, the findings of these trials have challenged 
previous hypotheses on the role of intermittent hypoxia 
in oxidative stress and vascular inflammation, and have 
suggested a so far unconfirmed mechanism of hypoxic 
preconditioning in OSA. 
Strengths and limitations of the CPAP withdrawal model
The CPAP withdrawal model is a very effective design 
to study the pathophysiological consequences of OSA 
and treatment effects in well-characterised patients. The 
recruitment rate is considerably faster, since it is based on 
databases of cohorts of already treated patients with OSA. 
Additionally, the duration of the intervention is limited. 
These two factors make the CPAP withdrawal model very 
time and cost effective. An additional advantage is that 
the short intervention period eliminates many potential 
confounders that do not change in the short-term (e.g., 
body mass index and an obesity effect), and the model 
allows OSA to be studied in a controlled fashion. The major 
benefit over conventional intention-to-treat randomised 
controlled CPAP trials, using previously therapy-naïve 
patients, is that a CPAP withdrawal study overcomes the 
compliance problem by only including patients previously 
optimally adherent to CPAP. Thereby, a maximal treatment 
effect can be assumed. Treatment-naïve patients with OSA 
may take time to become—or never become—established 
on CPAP therapy during the study period. The treatment 
effect in conventional CPAP trials is therefore usually 
diluted. Additionally, the effectiveness of novel therapies 
on OSA and its daytime symptoms can reliably be studied 
and compared to both continuing CPAP, the current 
gold-standard, as well as untreated OSA following CPAP 
withdrawal.
However, a major limitation is that the consequences 
of OSA recurrence during a short-term withdrawal of 
CPAP therapy cannot be equated to any long-term effects 
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of untreated OSA. The question of whether short- and 
long-term effects of untreated OSA are comparable 
remains unanswered. Finally, there will be a bias towards 
patients who are prepared to temporarily stop CPAP, 
which may mean that they have on average less severe 
OSA-related symptoms for example. Withdrawing CPAP 
results in increased daytime sleepiness and reduced driving 
performance (7,33,34). Therefore, one might raise a 
safety issue from withdrawing CPAP for 2 weeks. This is 
addressed by excluding professional drivers and patients 
with other vigilance-critical professions, informing patients 
about the expected increased sleepiness and reduced 
performance, and advising patients to avoid driving etc. 
during the study period if feeling at all sleepy. Therefore, 
the model is safe to evaluate treatment effects on OSA. In 
our experience, CPAP withdrawal has been well tolerated 
by the study participants, and CPAP holidays are common 
in real life.
Conclusions
The shor t - term CPAP wi thdrawal  mode l  o f fer s 
an experimental  protocol to effectively study the 
pathophysiological effects of OSA, as well as treatment 
effects in well-designed RCTs. Additionally, it can be used 
to provide RCT data on potential alternative treatment 
modalities in a head-to-head comparison with both CPAP 
and untreated OSA. 
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